

Development of Selective STAT6 Inhibitors for Eosinophilic Esophagitis and Th2 Inflammatory Immune Diseases

JW C&C Research Laboratories



IMMUNOLOGY	Candidate
Product Type	Small molecules
Indication	Eosinophilic Esophagitis and Th2 Inflammatory Immune Diseases
Target	STAT6
MoA(Mechanism of Action)	Directly binds to STAT6 and inhibits its activation → Regulating Th2-driven immune responses
Competitiveness	<ul style="list-style-type: none"> • An oral, selective STAT6 inhibitor (small molecule) • Targeting STAT6 offers strong therapeutic potential in Th2-driven inflammatory diseases • A novel therapy for patients with eosinophilic esophagitis which has highly unmet medical needs
Development Stage	Candidate
Route of Administration	Oral Administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.